Pressmeddelanden, rapporter och bolagsmeddelande för Inhalation Sciences

Spotlight News profile image

Spotlight News

Nyhetsuppdatering från Inhalation Sciences

Press release from Companies: Inhalation Sciences Sweden AB receives CTA approval for landmark clinical trial of PreciseInhale
Spotlight News profile image

Spotlight News

Nyhetsuppdatering från Inhalation Sciences

Press release from Companies: Inhalation Sciences signs exclusive distribution agreement with Sanyo Trading, Japan
Spotlight News profile image

Spotlight News

Nyhetsuppdatering från Inhalation Sciences

Press release from Companies: Inhalation Sciences: Senior KOLs and research experts join new ISAB Scientific Advisory Board
Spotlight News profile image

Spotlight News

Nyhetsuppdatering från Inhalation Sciences

Press release from Companies: Inhalation Sciences: Senior KOLs and research experts join new ISAB Scientific Advisory Board
Spotlight News profile image

Spotlight News

Nyhetsuppdatering från Inhalation Sciences

Press release from Companies: Inhalation Sciences Sweden AB (publ) releases Q1 Report 2021
Spotlight News profile image

Spotlight News

Nyhetsuppdatering från Inhalation Sciences

Press release from Companies: Inhalation Sciences Sweden AB (publ) publicerar delårsrapport första kvartalet 2021
Spotlight News profile image

Spotlight News

Nyhetsuppdatering från Inhalation Sciences

Press release from Companies: Inhalation Sciences Sweden AB (publ) releases Annual Report 2020
Spotlight News profile image

Spotlight News

Nyhetsuppdatering från Inhalation Sciences

Press release from Companies: Inhalation Sciences Sweden AB (publ) publicerar årsredovisning för 2020
Spotlight News profile image

Spotlight News

Nyhetsuppdatering från Inhalation Sciences

Press release from Companies: Inhalation Sciences Sweden AB (publ) publicerar årsredovisning för 2020
Spotlight News profile image

Spotlight News

Nyhetsuppdatering från Inhalation Sciences

Press release from Companies: Inhalation Sciences signs IRS contract worth 29 700 EUR with returning established pharma client